Sanofi (NASDAQ:SNY) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN lowered its holdings in Sanofi (NASDAQ:SNY) by 9.6% during the fourth quarter, Holdings Channel reports. The fund owned 2,255,360 shares of the company’s stock after selling 238,228 shares during the quarter. Wells Fargo & Company MN’s holdings in Sanofi were worth $112,159,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rise Advisors LLC grew its position in Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new position in Sanofi during the fourth quarter valued at $27,000. Venturi Wealth Management LLC lifted its holdings in Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares in the last quarter. McIlrath & Eck LLC lifted its holdings in Sanofi by 143.3% during the fourth quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after purchasing an additional 361 shares in the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in Sanofi by 115.6% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sanofi Trading Up 2.9 %

Shares of SNY stock opened at $50.36 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock has a market capitalization of $127.39 billion, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 1.52 and a beta of 0.61. The company has a 50 day moving average price of $48.25 and a 200 day moving average price of $48.20. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $55.72.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The firm had revenue of $11.36 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Equities research analysts predict that Sanofi will post 4.12 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a $1.478 dividend. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is 74.37%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.